Komori
Occurring Fact4564OncoTherapy Science,Inc.Pharmaceuticals

Notice concerning the change of certified public accountants and other auditors

The Company has decided that its accounting auditor will change from やまと監査法人 to 永和監査法人 upon the conclusion of the annual general meeting of shareholders scheduled for 23 June 2026. やまと監査法人 will retire upon expiration of its term, and 永和監査法人 is expected to assume office.

Worth reading
27Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Notice concerning the change of certified public accountants and other auditors

Subject Entity

OncoTherapy Science,Inc.

Occurrence23 June 2026 (the change is scheduled to take place upon the conclusion of the 25th Annual General Meeting of Shareholders)
Awareness or receipt of notice19 May 2026 (the date on which the Audit & Supervisory Board resolved to make the change)
This disclosure05/19/2026
Cause

やまと監査法人, the Company's accounting auditor, will reach the end of its term upon the conclusion of the 25th Annual General Meeting of Shareholders. In addition, based on a comparison and review of multiple accounting auditors using criteria including audit hours appropriate to the Company's business scale and operating environment, audit fees, expertise, agility, independence and quality control systems, the Company will appoint 永和監査法人 as its new accounting auditor.

Outlook

Upon the conclusion of the 25th Annual General Meeting of Shareholders scheduled for 23 June 2026, やまと監査法人 is expected to retire and 永和監査法人 is expected to assume office.

Event that occurred
ItemDetails
Event nameNotice concerning the change of certified public accountants and other auditors
Date of occurrence23 June 2026 (the change is scheduled to take place upon the conclusion of the 25th Annual General Meeting of Shareholders)
Date recognized / date notice received19 May 2026 (the date on which the Audit & Supervisory Board resolved to make the change)
Subject EntityOncoTherapy Science,Inc.
Causeやまと監査法人, the Company's accounting auditor, will reach the end of its term upon the conclusion of the 25th Annual General Meeting of Shareholders. In addition, based on a comparison and review of multiple accounting auditors using criteria including audit hours appropriate to the Company's business scale and operating environment, audit fees, expertise, agility, independence and quality control systems, the Company will appoint 永和監査法人 as its new accounting auditor.
OutlookUpon the conclusion of the 25th Annual General Meeting of Shareholders scheduled for 23 June 2026, やまと監査法人 is expected to retire and 永和監査法人 is expected to assume office.
Items this document does not state (19)
Target Locations / ProductsAmount of Impact on Business PerformanceAccounting period in which recognizedImpact on Earnings ForecastType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

やまと監査法人's term will expire upon the conclusion of the annual general meeting of shareholders. In addition, after comparing and reviewing multiple audit firms based on criteria including audit hours appropriate to the Company's business scale and operating environment, audit fees, expertise, agility, independence and quality control systems, the Company determined that 永和監査法人 was suitable.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice concerning the change of certified public accountants and other auditors | OncoTherapy Science,Inc. (4564) timely disclosure | Komori